Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy

The aim of this study is to validate the Fetal Medicine Foundation (FMF) multiple logistic regression algorithm for prediction of risk of pre‐eclampsia in an Australian population. This model, which predicts risk using the population rate of pre‐eclampsia, a variety of demographic factors, mean maternal arterial blood pressure (MAP), uterine artery PI (UtA PI) and pregnancy‐associated plasma protein A (PAPP‐A), has been shown to predict early‐onset pre‐eclampsia (delivery prior to 34 weeks) in 95% of women at a 10% false‐positive rate.

[1]  K. Nicolaides,et al.  Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP‐A at 11–13 weeks , 2010, Prenatal diagnosis.

[2]  K. Nicolaides,et al.  Protocol for Measurement of Mean Arterial Pressure at 11-13 Weeks' Gestation , 2012, Fetal Diagnosis and Therapy.

[3]  A. Seidler,et al.  Antiplatelet agents for preventing pre-eclampsia and its complications. , 2007, The Cochrane database of systematic reviews.

[4]  K. Nicolaides,et al.  Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia , 2013, Fetal Diagnosis and Therapy.

[5]  K. Nicolaides,et al.  Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach , 2010, Journal of Human Hypertension.

[6]  L. Stewart,et al.  Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data , 2007, The Lancet.

[7]  J. Simpson,et al.  Prevalence of pre‐eclampsia, pregnancy hypertension and gestational diabetes in population‐based data: Impact of different ascertainment methods on outcomes , 2012, The Australian & New Zealand journal of obstetrics & gynaecology.

[8]  M. Lindheimer,et al.  World Health Organization Systematic Review of Screening Tests for Preeclampsia , 2004, Obstetrics and gynecology.

[9]  G. Koren,et al.  Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. , 2002, American journal of obstetrics and gynecology.

[10]  R. Levine,et al.  First-trimester prediction of early preeclampsia: a possibility at last! , 2009, Hypertension.

[11]  K. Nicolaides,et al.  Maternal Serum Soluble Endoglin at 30-33 Weeks in the Prediction of Preeclampsia , 2012, Fetal Diagnosis and Therapy.

[12]  K. Nicolaides,et al.  Hypertensive Disorders in Pregnancy: Screening by Systolic Diastolic and Mean Arterial Pressure at 11–13 Weeks , 2011, Hypertension in pregnancy.

[13]  Cemach.  Saving mothers' lives: reviewing maternal deaths to make motherhood safer - 2003-2005 , 2007 .

[14]  K. Nicolaides,et al.  Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre‐eclampsia , 2007, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[15]  M. Egbor,et al.  Maternal medicine: Morphometric placental villous and vascular abnormalities in early‐ and late‐onset pre‐eclampsia with and without fetal growth restriction , 2006, BJOG : an international journal of obstetrics and gynaecology.

[16]  D. Isherwood,et al.  EFFECT OF ASPIRIN ON INCIDENCE OF PRE-ECLAMPSIA , 1979, The Lancet.

[17]  K. Nicolaides,et al.  Uterine Artery Doppler at 30-33 Weeks' Gestation in the Prediction of Preeclampsia , 2013, Fetal Diagnosis and Therapy.

[18]  Jean-Marie Moutquin,et al.  The Classification and Diagnosis of the Hypertensive Disorders of Pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP) , 2001, Hypertension in pregnancy.

[19]  L. Bowyer.  The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer 2003–2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the UK , 2008 .

[20]  S. Michie,et al.  Assessing the psychological effects of prenatal screening tests for maternal and foetal conditions: a systematic review , 2012 .

[21]  P. Beeby,et al.  New South Wales population‐based birthweight percentile charts , 1996, Journal of paediatrics and child health.

[22]  Kypros H Nicolaides,et al.  An integrated model for the prediction of pre-eclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. , 2006, American journal of obstetrics and gynecology.

[23]  K. Nicolaides,et al.  Mean Arterial Pressure at 11+0 to 13+6 Weeks in the Prediction of Preeclampsia , 2008, Hypertension.

[24]  Kirsten Duckitt,et al.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies , 2005, BMJ : British Medical Journal.

[25]  K. Nicolaides,et al.  Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks , 2010, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[26]  François Audibert,et al.  Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy: A Meta-Analysis , 2010, Obstetrics and gynecology.

[27]  K. Nicolaides,et al.  Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11–13 weeks , 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[28]  A. Weindling,et al.  The confidential enquiry into maternal and child health (CEMACH) , 2003, Archives of disease in childhood.

[29]  Argyro Syngelaki,et al.  Prediction of early, intermediate and late pre‐eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks , 2011, Prenatal diagnosis.

[30]  K. Nicolaides,et al.  Prevention of Perinatal Death and Adverse Perinatal Outcome Using Low-Dose Aspirin: A Meta-Analysis , 2013 .

[31]  I. Staboulidou,et al.  Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11–13 weeks , 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[32]  A. Shennan,et al.  An accurate automated blood pressure device for use in pregnancy and pre‐eclampsia: the Microlife 3BTO‐A , 2005, BJOG : an international journal of obstetrics and gynaecology.

[33]  B. Sibai,et al.  The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. , 2003, American journal of obstetrics and gynecology.

[34]  Kypros H Nicolaides,et al.  An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. , 2005, American journal of obstetrics and gynecology.